Evidence map›Paper›PMID 38654284›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2024

Radiomics signature for dynamic changes of tumor-infiltrating CD8+ T cells and macrophages in cervical cancer during chemoradiotherapy.

Kang Huang, Xuehan Huang, Chengbing Zeng, Siyan Wang, Yizhou Zhan, Qingxin Cai, Guobo Peng, Zhining Yang, Li Zhou, Jianzhou Chen and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Associations between ADC histogram analysis values and tumor-micro milieu in uterine cervical cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Kang Huang *Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, P.R. China.
Xuehan Huang *Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, P.R. China.
Chengbing Zeng *Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, P.R. China.
Siyan WangDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, P.R. China.
Yizhou ZhanDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, P.R. China.
Qingxin CaiDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, P.R. China.
Guobo PengDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, P.R. China.
Zhining YangDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, P.R. China.
Li ZhouDepartment of Gynecologic Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China.
Jianzhou ChenDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, P.R. China. cjzeoeo@gmail.com.
Chuangzhen ChenDepartment of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou, P.R. China. czchen2@stu.edu.cn.ORCID http://orcid.org/0000-0002-2342-8099
Shantou University · CNInserm · FR

Funding

the Clinical Research Project of the Cancer Hospital of Shantou University Medical College 2023B001the Innovative Research Group Project of the National Natural Science Foundation of China 82173079the Natural Science Foundation of Guangdong Province of China 2022A1515011220the Natural Science Foundation of Guangdong Province of China 2022A1515220007the Science and Technology Bureau of Shantou 200110115871710the Science and Technology Special Fund of Guangdong Province of China 2019-132the Shantou Science and Technology Plan Medical and Health Category Project 210408216492660the Shantou Science and Technology Plan Medical and Health Category Project 230509116495546the Shantou University Medical College Clinical Research Enhancement Initiative N0201424the Strategic and Special Fund for Science and Technology Innovation of Guangdong Province of China 180918114960704
6 · The paper itself

Abstract

backgroundOur previous study suggests that tumor CD8+ T cells and macrophages (defined as CD68+ cells) infiltration underwent dynamic and heterogeneous changes during concurrent chemoradiotherapy (CCRT) in cervical cancer patients, which correlated with their short-term tumor response. This study aims to develop a CT image-based radiomics signature for such dynamic changes.

methodsThirty cervical squamous cell carcinoma patients, who were treated with CCRT followed by brachytherapy, were included in this study. Pre-therapeutic CT images were acquired. And tumor biopsies with immunohistochemistry at primary sites were performed at baseline (0 fraction (F)) and immediately after 10F. Radiomics features were extracted from the region of interest (ROI) of CT images using Matlab. The LASSO regression model with ten-fold cross-validation was utilized to select features and construct an immunomarker classifier and a radiomics signature. Their performance was evaluated by the area under the curve (AUC).

resultsThe changes of tumor-infiltrating CD8+T cells and macrophages after 10F radiotherapy as compared to those at baseline were used to generate the immunomarker classifier (AUC= 0.842, 95% CI:0.680-1.000). Additionally, a radiomics signature was developed using 4 key radiomics features to predict the immunomarker classifier (AUC=0.875, 95% CI:0.753-0.997). The patients stratified based on this signature exhibited significant differences in treatment response (p = 0.004).

conclusionThe radiomics signature could be used as a potential predictor for the CCRT-induced dynamic alterations of CD8+ T cells and macrophages, which may provide a less invasive approach to appraise tumor immune status during CCRT in cervical cancer compared to tissue biopsy.

Indexed as

CD8-Positive T-LymphocytesChemoradiotherapyLymphocytes, Tumor-InfiltratingMacrophagesUterine Cervical NeoplasmsAdultAgedBrachytherapyCarcinoma, Squamous CellFemaleHumansMiddle AgedRadiomicsTomography, X-Ray ComputedCD8+ T cellsConcurrent chemoradiotherapyImmunomarker classifierMacrophagesRadiomics signature

Identifiers

PMID38654284
PMCPMC11036574
OpenAlexW4395043536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.